Drug Resistance Updates
Publisher: Elsevier · ISSN 1368-7646 · 45 articles
- Cysteine acquisition in cancer: Cystine import or glutathione catabolism?
- Corrigendum to “Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer resistance to cancer immunotherapy” [Drug Resist. Updates, Vol. 90, January 2027, 101473]
- Editorial Board
- ZDHHC16-induced GPX2 S-palmitoylation promotes lenvatinib resistance and inhibits lenvatinib-induced immunogenic cell death in hepatocellular carcinoma
- A multifunctional antimicrobial peptide with cell-penetrating and β-lactam-potentiating activities for combating methicillin-resistant Staphylococcus aureus and carbapenem-resistant Enterobacteriaceae infections
- MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer
- Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance
- ITPKB suppresses ER calcium release to promote CXCL9 expression and enhance immunotherapy sensitivity in triple-negative breast cancer
- ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma
- OGT-mediated O-GlcNAcylation of BICD2 drives gemcitabine resistance in pancreatic cancer via accelerating G2/M cell cycle progression
- Tumor-intrinsic PHGDH inhibition sensitizes colorectal cancer to PD-1 blockade via α-ketoglutarate–mediated macrophage reprogramming
- Piperidine-derived resensitizers revive aminoglycoside capacity against persister cells of Pseudomonas aeruginosa in vivo
- Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies
- Immunotherapy in cancer: Mechanisms and strategies to overcome resistance
- Biomimetic delivery systems for overcoming drug resistance in gastrointestinal cancers
- Consensus on standardized later-line systemic therapy for hepatocellular carcinoma
- Extracellular matrix stiffness and mechanotransduction in cancer drug resistance
- Corrigendum to “CSDE1 enhances genotoxic drug resistance in cancer by modulating RPA2 through the CSDE1–eIF3a regulatory complex” [Drug Resist. Updat. 81 (2025) 101249]
- Fit-for-purpose 3D cancer models for therapy resistance research: an evidence framework from observation to causation
- Cancer-Associated Fibroblasts Promote Thyroid Cancer Progression and Reduce Radioiodide Uptake via Lactylation
- Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer immunotherapy resistance in lung cancer
- Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway
- Nucleolin shields PTBP1 from autophagic degradation to sustain gemcitabine resistance in bladder cancer
- UBR5-KDM5A axis rewires redox metabolism to confer cisplatin resistance in triple-negative breast cancer via the cAMP-PKA-SIRT3 cascade
- Nationwide dalbavancin surveillance identifies sagB-associated cell-wall adaptation linked to reduced lipoglycopeptide susceptibility in CC5 Staphylococcus aureus
- SRSF1-DLAT axis drives mitochondrial fusion to confer therapy resistance in diabetes-associated pancreatic ductal adenocarcinoma
- Genomic dynamics and macrolide resistance in Bordetella pertussis: implications for surveillance and rapid visual detection
- Targeting V-ATPase assembly via sEVs-delivered doxorubicin triggers methuosis and circumvents temozolomide resistance in glioblastoma
- PKA-dependent phosphorylation of PSMG1 reduces bortezomib sensitivity in hepatocellular carcinoma
- Calibrating public genome archives for AMR surveillance: Four decades of redundancy-aware phylogenomics of pandemic Escherichia coli ST131